Think of this as a game of regulatory limbo where you stay below the line of what an acquisition is.It’s a licensing deal.It’s only 49%.It’s a dividend.It’s all the personnel, but temporarily.And so on. You see the line, and you stay on the right side of the line. https://t.co/KeuBHKWdSvAntoun Nabhan (@AntounNabhan):@balajis You mean “license” the assets. Outright asset acquisition is a typical M&A. ...

Celebrities have long used fame to peddle things. But many are now rethinking the value of traditional endorsement and licensing deals.Instead they’re launching their own businesses https://t.co/h6h5Ck1KlJ ...

Asia Pacific Equity Research 12 June 2025 (852) 2800 8195 denise.yan@jpmorgan.com J.P. Morgan Securities (Asia Pacific) Limited/ J.P. Morgan Broking (Hong Kong) Limited J P M O R G A N Correction (first published 11 June 2025) (See disclosures for details) China Biotech Thoughts on the road ahead for Innovent, Akeso and Kelun-Biotech As we continue to receive questions on Innovent, Akeso and Kelun-Biotech during our marketing tour and in light of recent news flow on these three names, we offer some of our q ...